ADMA Biologics (NASDAQ:ADMA) Trading Down 5.5% - Should You Sell?

Key Points

• ADMA Biologics shares fell 5.5% to about $8.64, with trading volume down 89% from the average daily level.
• Analysts maintain a “Moderate Buy” consensus, with three Buy and three Hold ratings and an average price target of $18.67—well above the recent share price.
• The company met quarterly EPS expectations at $0.16, while revenue reached $124.39 million and rose 2% year over year. Institutional investors own approximately 75.68% of outstanding shares.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report)'s stock price traded down 5.5% during trading on Tuesday . The company traded as low as $8.66 and last traded at $8.6350. Approximately 452,434 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 4,254,918 shares. The stock had previously closed at $9.14.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of recent research reports. Raymond James Financial initiated coverage on ADMA Biologics in a research report on Wednesday, June 10th. They issued an "outperform" rating and a $21.00 target price for the company. Zacks Research upgraded ADMA Biologics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, September 2nd. Weiss Ratings restated a "hold (c)" rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Finally, Mizuho cut their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Wednesday, July 15th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $18.67.

ADMA Biologics Price Performance

The stock has a market capitalization of $1.96 billion, a PE ratio of 12.48 and a beta of 0.78. The business's 50-day moving average price is $9.23 and its 200 day moving average price is $9.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The firm's quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the company earned $0.14 earnings per share. Research analysts forecast that ADMA Biologics Inc will post 0.78 earnings per share for the current year.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in ADMA Biologics by 448.8% during the 1st quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company's stock valued at $8,373,000 after acquiring an additional 759,984 shares during the period. Bank of America Corp DE lifted its position in ADMA Biologics by 107.5% in the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company's stock valued at $36,019,000 after purchasing an additional 2,071,338 shares during the last quarter. Louisiana State Employees Retirement System purchased a new stake in shares of ADMA Biologics during the first quarter valued at approximately $951,000. BNP Paribas Financial Markets grew its holdings in shares of ADMA Biologics by 2,188.4% in the fourth quarter. BNP Paribas Financial Markets now owns 1,141,106 shares of the biotechnology company's stock worth $20,814,000 after purchasing an additional 1,091,241 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd increased its stake in shares of ADMA Biologics by 1,508.1% in the first quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company's stock worth $9,690,000 after buying an additional 1,008,548 shares during the period. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company's activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA's marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.